Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + BCG in HER2+ High-risk NMIBC
NCT06187506Phase 2Active, not recruiting
- Sponsor
- Fudan University
- Start
- Dec 2023
- Primary completion
- Sep 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of disitamab vedotin in non-muscle-invasive bladder cancer (NMIBC), sponsored by Fudan University. Primary endpoints: Complete Response Rate at 3 months and Event-Free Survival Rate at 6 months. Started Dec 2023; status: active, not recruiting.
02
Drugs
disitamab vedotin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06187506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06187506.